Table 1.
Comparison of the Mutations in CTCs with Correspondent Primary Tumor Tissue in Single Genes in Different Subgroups
| No. of Patients | CTC+PTT+ | CTC+PTT− | CTC−PTT+ | Concordance | |
|---|---|---|---|---|---|
| Total | 722 | 383 | 117 | 222 | 0.530 |
| Disease | |||||
| Melanoma | 65 | 52 | 8 | 5 | 0.800 |
| Lung cancer | 276 | 205 | 27 | 44 | 0.743 |
| Colorectal cancer | 177 | 98 | 30 | 49 | 0.554 |
| Breast cancer | 204 | 28 | 52 | 124 | 0.137 |
| Mutation | |||||
| EGFR | 93 | 70 | 5 | 18 | 0.753 |
| BRAF | 78 | 58 | 8 | 12 | 0.744 |
| KRAS | 347 | 227 | 52 | 68 | 0.654 |
| PIK3CA | 204 | 28 | 52 | 124 | 0.137 |
| Country | |||||
| China | 192 | 155 | 15 | 22 | 0.807 |
| The Netherlands | 15 | 2 | 4 | 9 | 0.133 |
| Greece | 195 | 48 | 31 | 116 | 0.246 |
| United States | 55 | 33 | 9 | 13 | 0.60 |
| Singapore | 37 | 13 | 7 | 17 | 0.351 |
| France | 75 | 56 | 12 | 7 | 0.747 |
| Italy | 39 | 32 | 1 | 6 | 0.821 |
| Germany | 62 | 21 | 25 | 16 | 0.339 |
| UK | 28 | 10 | 9 | 9 | 0.357 |
| Japan | 7 | 6 | 1 | 0 | 0.857 |
| Brazil | 9 | 5 | 2 | 2 | 0.556 |
| Spain | 8 | 2 | 1 | 5 | 0.250 |
| Method | |||||
| Magnetically sensed antibody sandwich assays | 4 | 4 | 0 | 0 | 1.000 |
| Scorpion amplification refractory mutation system technology | 20 | 19 | 0 | 1 | 0.950 |
| Whole-genome amplification and Sanger sequencing | 10 | 9 | 1 | 0 | 0.900 |
| RELP-PCR | 34 | 29 | 3 | 2 | 0.853 |
| NGS | 37 | 31 | 0 | 6 | 0.838 |
| Membrane arrays | 190 | 153 | 15 | 22 | 0.805 |
| Immunohistochemistry | 59 | 46 | 8 | 5 | 0.780 |
| dd-PCR | 16 | 10 | 4 | 2 | 0.625 |
| The peptide nucleic acid (PNA)-mediated PCR clamp with TaqMan-MGB allelic discrimination assays | 13 | 5 | 2 | 6 | 0.385 |
| PCR sequencing | 157 | 51 | 52 | 54 | 0.325 |
| Quantitative real-time PCR | 14 | 3 | 5 | 6 | 0.214 |
| Melting analysis | 168 | 23 | 27 | 118 | 0.137 |
The concordance rate of mutations between CTCs and matched primary tumor was as follows: sum of patients with mutation existing in both CTCs and tumor tissue/sum of all patients. CTC, circulating tumor cell; dd-PCR, digital PCR; NGS, next-generation sequencing; PTT, primary tumor tissue; RELP-PCR, restriction fragment length polymorphism-PCR.